Barclays PLC Boosts Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

Barclays PLC boosted its position in scPharmaceuticals Inc. (NASDAQ:SCPHFree Report) by 317.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,644 shares of the company’s stock after buying an additional 30,902 shares during the quarter. Barclays PLC’s holdings in scPharmaceuticals were worth $186,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Rubric Capital Management LP boosted its holdings in scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after buying an additional 1,250,000 shares during the period. Bank of Montreal Can purchased a new stake in shares of scPharmaceuticals during the second quarter worth $1,544,000. King Luther Capital Management Corp boosted its holdings in shares of scPharmaceuticals by 51.8% in the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock worth $9,592,000 after acquiring an additional 752,005 shares during the period. Rice Hall James & Associates LLC grew its position in shares of scPharmaceuticals by 76.9% in the second quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock valued at $2,163,000 after purchasing an additional 216,122 shares in the last quarter. Finally, Suvretta Capital Management LLC purchased a new position in shares of scPharmaceuticals in the third quarter valued at $9,343,000. 89.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Craig Hallum cut their target price on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, November 14th.

Get Our Latest Analysis on SCPH

scPharmaceuticals Stock Down 1.7 %

SCPH opened at $3.56 on Wednesday. The business’s 50-day moving average price is $3.61 and its 200-day moving average price is $4.30. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. scPharmaceuticals Inc. has a 12 month low of $3.08 and a 12 month high of $6.54. The company has a market cap of $178.14 million, a P/E ratio of -1.87 and a beta of 0.11.

About scPharmaceuticals

(Free Report)

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

Featured Articles

Want to see what other hedge funds are holding SCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for scPharmaceuticals Inc. (NASDAQ:SCPHFree Report).

Institutional Ownership by Quarter for scPharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.